PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
2.22%
Revenue growth of 2.22% vs. zero growth in Medical - Pharmaceuticals. Walter Schloss might still want to see if it can translate into profits.
0.43%
Gross profit growth of 0.43% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a slight advantage that could be built upon.
3.96%
EBIT growth exceeding 1.5x Medical - Pharmaceuticals median of 1.75%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
4.58%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 3.02%. Joel Greenblatt would see if unique processes drive exceptional profitability.
3.45%
Net income growth 1.25-1.5x Medical - Pharmaceuticals median of 2.63%. Mohnish Pabrai would confirm consistent strategy or niche leadership behind these results.
3.44%
EPS growth near Medical - Pharmaceuticals median of 3.33%. Charlie Munger might conclude it’s in line with industry norms.
3.44%
Diluted EPS growth near Medical - Pharmaceuticals median of 3.33%. Charlie Munger would expect typical industry-level share usage and profit trends.
-0.00%
Share reduction while Medical - Pharmaceuticals median is 0.11%. Seth Klarman would see a relative advantage if others are diluting.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.12%. Seth Klarman would see an advantage if others are still diluting.
No Data
No Data available this quarter, please select a different quarter.
4.61%
OCF growth 1.25-1.5x Medical - Pharmaceuticals median of 3.63%. Mohnish Pabrai would verify if these gains stem from sustainable core operations.
4.61%
FCF growth 1.25-1.5x Medical - Pharmaceuticals median of 4.08%. Mohnish Pabrai might attribute it to efficient operations or capital spending.
24.33%
10Y revenue/share CAGR 75-90% of Medical - Pharmaceuticals median of 32.19%. John Neff would seek operational improvements to catch up with peers.
44.56%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 16.27%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
20.69%
3Y revenue/share growth 1.25-1.5x Medical - Pharmaceuticals median of 17.55%. Mohnish Pabrai would attribute it to strong near-term market positioning.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
23.06%
Net income/share CAGR 1.25-1.5x Medical - Pharmaceuticals median. Mohnish Pabrai would confirm that management’s capital allocation strategy drives the outperformance.
21.77%
5Y net income/share CAGR > 1.5x Medical - Pharmaceuticals median of 4.32%. Joel Greenblatt might see superior mid-term capital allocation or product strength.
-8.85%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 8.08%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
138.51%
Equity/share CAGR of 138.51% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
97.30%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.84%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
46.99%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 14.56%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
No Data
No Data available this quarter, please select a different quarter.
88.89%
5Y dividend/share CAGR of 88.89% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
-2.02%
AR shrinking while Medical - Pharmaceuticals median grows. Seth Klarman sees potential advantage unless it signals declining demand.
-1.88%
Decreasing inventory while Medical - Pharmaceuticals is rising. Seth Klarman might see an efficiency advantage or possibly a sign of weaker sales future.
-0.52%
Assets shrink while Medical - Pharmaceuticals median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
1.65%
Positive BV/share change while Medical - Pharmaceuticals median is negative. Peter Lynch finds a strong advantage vs. peers failing to expand equity.
73.31%
Slightly rising debt while Medical - Pharmaceuticals median is deleveraging. Peter Lynch wonders if the firm lags behind peers in risk control or invests in more expansions.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
SG&A decline while Medical - Pharmaceuticals grows. Seth Klarman sees potential cost advantage or a risk if it hurts future growth.